DelveInsight’s report, “Common Warts Market Insights, Epidemiology, and Market Forecast – 2034,” delivers a detailed evaluation of the disease, including both historical and projected epidemiological trends, along with comprehensive market analysis across the United States, EU4 countries (Germany, Spain, Italy, France), the United Kingdom, and Japan.
The report provides a thorough overview of current treatment approaches, emerging therapeutic candidates, and the market share held by individual therapies. It also presents the present and future market size of Common Warts from 2019 to 2032 across the seven major markets.
Additionally, the study highlights existing treatment algorithms, key growth drivers, potential barriers, and unmet medical needs, offering valuable insights to identify growth opportunities and assess the overall potential of the Common Warts market.
To Know in detail about the Common Warts market outlook, drug uptake, treatment scenario and epidemiology trends, Click here; Common Warts Market Forecast
Some of the key facts of the Common Warts Market Report:
- The Common Warts market size was valued approximately USD 725 million in 2022 and is anticipated to grow with a significant CAGR during the study period (2020-2034)
- Key Common Warts Companies: KinoPharma Inc., Veradermics, Inc., Labo’Life, Merck Sharp & Dohme LLC, Shanghai Zerun Biotechnology, X4 Pharmaceuticals, Nielsen BioSciences, Verrica Pharmaceutical, Kino Pharma/ Iwaki Pharmaceutical, Aclaris Therapeutics, Inc., KinoPharma Inc., ViroXis Corporation, Maruho Co., Ltd., Veradermics, Inc., Graceway Pharmaceuticals, LLC, MEDA Pharma, LEO Pharma, and others
- Key Common Warts Therapies: KNP2002, VDMN-21, 2LVERU® or 2LVERU® JUNIOR, V503, Zerun HPV-9, Mavorixafor, CANDIN, VP-102, FIT039, A-101, KNP2002, 10% EISO, CLS006, VDMN-21, Resiquimod, Imiquimod, Picato, and others
- In January 2026, Verrica Pharmaceuticals Inc. recently announced the launch of a global Phase III clinical development program to evaluate VP-102 for the treatment of common warts, with the first patient dosed in December 2025. This development marks an expansion of VP-102’s clinical scope beyond its currently approved use for molluscum contagiosum and underscores the company’s continued commitment to addressing unmet needs in dermatology.
- In July 2025, Verrica’s efforts to develop a treatment for common warts are poised to receive a $18 million boost following an amended licensing agreement. The revised deal terms are expected to accelerate the company’s progress toward introducing the first FDA-approved prescription therapy for common warts.
- In May 2025, Verrica Pharmaceuticals Inc. (Nasdaq: VRCA) announced progress in its late-stage development pipeline, highlighted by the completion of an end-of-Phase 2 meeting with the U.S. Food and Drug Administration (FDA) for VP-315, the company’s investigational treatment for basal cell carcinoma. Additionally, Verrica is making strides toward launching a global Phase 3 clinical program for VP-102/YCANTH, its treatment candidate for common warts, in collaboration with its partner, Torii Pharmaceutical.
- In February 2025, Nielsen BioSciences, Inc., a privately held biopharmaceutical company headquartered in San Diego, announced the successful enrollment of the final participant in its Phase 3 clinical trial, CFW-3A. This randomized, double-blind, placebo-controlled study is evaluating the safety and efficacy of CANDIN® (Candida albicans Skin Test Antigen for Cellular Hypersensitivity) for treating common warts (Verruca vulgaris) in both adolescents and adults. It’s important to note that CANDIN is not yet approved for this indication.
- In November 2024, Veradermics, Inc announced results of Protocol 250-1951-201: A Phase 2, Multi-Center, Randomized, Double-Blind, Vehicle-Controlled Study of the Safety and Efficacy of VDMN-21 in Subjects With Verruca Vulgaris
- In October 2024, Labo’Life has announced a Study to Evaluate the Efficacy of 2LVERU® JUNIOR and 2LVERU® on the Treatment of Warts.
- According to DelveInsight’s evaluation, in 2022, the total number of diagnosed prevalent cases of common warts in the 7MM was estimated to be around 14,964,357 cases.
- In the 7MM, the United States accounted for the highest number of diagnosed prevalent cases of common warts in 2022, totalling approximately 2,824,294 cases. This represented nearly 19% of the total diagnosed prevalent cases in the 7MM.
- In 2022, the EU4 countries and the UK collectively had around 10,779,827 diagnosed prevalent cases of common warts.
- This constituted the majority of cases, covering an estimated 72% of the total cases in the 7MM.
- In the EU4 countries and the UK, Germany had the highest total number of diagnosed prevalent cases of common warts in 2022, totaling approximately 2,628,032 cases. This was followed by France and the UK, with approximately 2,247,383 and 2,184,658 cases respectively.
- The Common Warts epidemiology based on gender analyzed that the diagnosed prevalent cases were observed to be same for male and female in the 7MM
- The Common Warts market is expected to surge due to the disease’s increasing prevalence and awareness during the forecast period. Furthermore, launching various multiple-stage Common Warts pipeline products will significantly revolutionize the Common Warts market dynamics.
Common Warts Overview
Common warts, also known as verruca vulgaris, are benign skin growths caused by the human papillomavirus (HPV), primarily types 2, 4, 27, and 57. They develop when the virus infects the top layer of the skin, often through small cuts or abrasions. Common warts are highly contagious, spreading through direct skin contact or contaminated surfaces.
These warts appear as rough, raised, skin-colored or grayish lesions with a cauliflower-like texture. They are most commonly found on the hands, fingers, elbows, and knees, though they can occur anywhere on the body. While generally painless, they may cause discomfort or irritation, especially in high-friction areas.
Diagnosis is typically clinical, based on their characteristic appearance. In uncertain cases, a skin biopsy may be performed. Most common warts resolve spontaneously over time, but treatment may be necessary for persistent or bothersome lesions. Options include topical salicylic acid, cryotherapy (freezing with liquid nitrogen), laser therapy, electrosurgery, and immunotherapy. Preventive measures such as good hygiene, avoiding direct contact with warts, and strengthening the immune system can reduce the risk of infection. Ongoing research into antiviral therapies and immune-modulating treatments is expanding future treatment possibilities for common warts.
Get a Free sample for the Common Warts Market Report: https://www.delveinsight.com/sample-request/common-warts-market
Common Warts Epidemiology
The epidemiology section provides insights into the historical, current, and forecasted epidemiology trends in the seven major countries (7MM) from 2020 to 2034. It helps to recognize the causes of current and forecasted trends by exploring numerous studies and views of key opinion leaders. The epidemiology section also provides a detailed analysis of the diagnosed patient pool and future trends.
Common Warts Epidemiology Segmentation:
The Common Warts market report proffers epidemiological analysis for the study period 2020–2034 in the 7MM segmented into:
- Total Prevalence of Common Warts
- Prevalent Cases of Common Warts by severity
- Gender-specific Prevalence of Common Warts
- Diagnosed Cases of Episodic and Chronic Common Warts
Download the report to understand which factors are driving Common Warts epidemiology trends @ Common Warts Epidemiology Forecast
Common Warts Drugs Uptake and Pipeline Development Activities
The drugs uptake section focuses on the rate of uptake of the potential drugs recently launched in the Common Warts market or expected to get launched during the study period. The analysis covers Common Warts market uptake by drugs, patient uptake by therapies, and sales of each drug.
Moreover, the therapeutics assessment section helps understand the drugs with the most rapid uptake and the reasons behind the maximal use of the drugs. Additionally, it compares the drugs based on market share.
The report also covers the Common Warts Pipeline Development Activities. It provides valuable insights about different therapeutic candidates in various stages and the key companies involved in developing targeted therapeutics. It also analyzes recent developments such as collaborations, acquisitions, mergers, licensing patent details, and other information for emerging therapies.
Common Warts Therapies and Key Companies
- KNP2002: KinoPharma Inc.
- 2LVERU® or 2LVERU® JUNIOR: Labo’Life
- V503: Merck Sharp & Dohme LLC
- Zerun HPV-9: Shanghai Zerun Biotechnology
- Mavorixafor: X4 Pharmaceuticals
- CANDIN: Nielsen BioSciences/Maruho
- VP-102: Verrica Pharmaceutical
- FIT039: Kino Pharma/ Iwaki Pharmaceutical
- A-101: Aclaris Therapeutics, Inc.
- KNP2002: KinoPharma Inc.
- 10% EISO: ViroXis Corporation
- CLS006: Maruho Co., Ltd.
- VDMN-21: Veradermics, Inc.
- Resiquimod: Graceway Pharmaceuticals, LLC
- Imiquimod: MEDA Pharma
- Picato: LEO Pharma
To know more about latest happenings in Common Warts, visit @ Common Warts Medication and Treatment Market
Common Warts Market Strengths
The rising prevalence of warts is encourages companies in the life sciences industry to focus on research and development of new drugs for warts treatment. There is a continuous need for new, innovative therapeutic approaches for better treatment outcomes. An increase in emerging new drugs for the treatment of warts will lead to better patient outcomes in the coming years.
Common Warts Market Opportunities
Recent studies have shown the safe and efficacious role of Zinc supplementation in warts clearance, particularly for patients who have not responded to treatments previously.
Secondary research on the warts therapeutics market suggests that the market is saturated with limited drug opportunities providing the key Pharma players a successful domain to work with utmost robustness
Scope of the Common Warts Market Report
- Study Period: 2020–2034
- Coverage: 7MM [The United States, EU5 (Germany, France, Italy, Spain, and the United Kingdom), and Japan]
- Key Common Warts Companies: KinoPharma Inc., Veradermics, Inc., Labo’Life, Merck Sharp & Dohme LLC, Shanghai Zerun Biotechnology, X4 Pharmaceuticals, Nielsen BioSciences, Verrica Pharmaceutical, Kino Pharma/ Iwaki Pharmaceutical, Aclaris Therapeutics, Inc., KinoPharma Inc., ViroXis Corporation, Maruho Co., Ltd., Veradermics, Inc., Graceway Pharmaceuticals, LLC, MEDA Pharma, LEO Pharma, and others
- Key Common Warts Therapies: KNP2002, VDMN-21, 2LVERU® or 2LVERU® JUNIOR, V503, Zerun HPV-9, Mavorixafor, CANDIN, VP-102, FIT039, A-101, KNP2002, 10% EISO, CLS006, VDMN-21, Resiquimod, Imiquimod, Picato, and others
- Common Warts Therapeutic Assessment: Common Warts current marketed and Common Warts emerging therapies
- Common Warts Market Dynamics: Common Warts market drivers and Common Warts market barriers
- Competitive Intelligence Analysis: SWOT analysis, PESTLE analysis, Porter’s five forces, BCG Matrix, Market entry strategies
- Common Warts Unmet Needs, KOL’s views, Analyst’s views, Common Warts Market Access and Reimbursement
To know more about Common Warts companies working in the treatment market, visit @ Common Warts Clinical Trials and Therapeutic Assessment
Table of Contents
1. Common Warts Market Report Introduction
2. Executive Summary for Common Warts
3. SWOT analysis of Common Warts
4. Common Warts Patient Share (%) Overview at a Glance
5. Common Warts Market Overview at a Glance
6. Common Warts Disease Background and Overview
7. Common Warts Epidemiology and Patient Population
8. Country-Specific Patient Population of Common Warts
9. Common Warts Current Treatment and Medical Practices
10. Common Warts Unmet Needs
11. Common Warts Emerging Therapies
12. Common Warts Market Outlook
13. Country-Wise Common Warts Market Analysis (2020–2034)
14. Common Warts Market Access and Reimbursement of Therapies
15. Common Warts Market Drivers
16. Common Warts Market Barriers
17. Common Warts Appendix
18. Common Warts Report Methodology
19. DelveInsight Capabilities
20. Disclaimer
21. About DelveInsight
About DelveInsight
DelveInsight is a leading Healthcare Business Consultant, and Market Research firm focused exclusively on life sciences. It supports Pharma companies by providing comprehensive end-to-end solutions to improve their performance.
Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Ankit Nigam
Email: Send Email
Phone: +14699457679
Address:304 S. Jones Blvd #2432
City: Albany
State: New York
Country: United States
Website: https://www.delveinsight.com/consulting